Syra Health CEO granted RSUs and stock options

Syra Health Corp. reported that CEO Gregory R. Alexander received new equity awards.

Accepted by SEC EDGAR 02/03/2026 - 04:30 PM EST Learn about SEC filing dates

The filer has since corrected this document, so the figures below are the ones originally reported and some of them may have changed. Read the amended Form 4/A for what the company says now.

Rhea-AI Filing Summary

Syra Health Corp. reported that CEO Gregory R. Alexander received new equity awards. On January 5, 2026, he was granted 110,537 restricted stock units at $0.00 per unit and 257,920 stock options with a $0.09 exercise price.

For both grants, 20% vest one year after the grant date. The remaining 80% vest in equal installments over the following four years on each anniversary of the grant date, aligning his compensation with longer-term company performance.

Insider Trade Summary

Grant/Award: 368,457 shares

Grant/Award 2 txns

Insider Alexander Gregory R.

Role CEO

Type	Security	Shares	Price	Value
Grant/Award	Stock Options	257,920	$0.00	$0.00
Grant/Award	Restricted Stock Units	110,537	$0.00	$0.00

Holdings After Transaction: Stock Options — 257,920 contracts (Direct); Restricted Stock Units — 110,537 shares (Direct)

Footnotes (2)

1. F1. 20% of the RSUs vest one year after date of grant and the remainder vest equally over four years on the anniversary of date of grant beginning one year after date of grant
2. F2. 20% of the options vest one year after date of grant and the remainder vest equally over four years on the anniversary of the date of grant beginning one year after date of grant.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Syra Health (SYRA) report for the CEO?

Syra Health reported that CEO Gregory R. Alexander received equity awards on January 5, 2026. He was granted 110,537 restricted stock units and 257,920 stock options, aligning his compensation with the company’s long-term performance through multi-year vesting schedules.

How many restricted stock units did the Syra Health CEO receive?

The Syra Health CEO received 110,537 restricted stock units. These RSUs were granted at a price of $0.00 per unit and are structured to vest over several years, tying the CEO’s potential share ownership to continued service and company performance.

What stock option grant did the Syra Health (SYRA) CEO receive?

The CEO received 257,920 stock options with an exercise price of $0.09 per share. These options give him the right to buy Syra Health Class A common stock at that price if they vest and are exercised before their stated expiration date.

What is the vesting schedule for the Syra Health CEO’s RSUs?

For the CEO’s RSUs, 20% vest one year after the grant date. The remaining 80% then vest in equal installments over four years on each anniversary, encouraging multi-year retention and performance alignment with Syra Health shareholders.

How do the Syra Health CEO’s stock options vest over time?

The CEO’s stock options follow the same pattern as his RSUs. Twenty percent vest one year after the January 5, 2026 grant date, and the remaining 80% vest equally over the next four years on each anniversary, subject to continued service.

When do the newly granted Syra Health stock options expire?

The granted stock options for the Syra Health CEO expire on January 5, 2036. This long-dated expiration gives a multi-year window during which, once vested, the CEO may choose to exercise the options at the $0.09 per share exercise price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Alexander Gregory R.

(Last) (First) (Middle)

C/O SYRA HEALTH CORP.

1119 KEYSTONE WAY N., #201

(Street)

CARMEL IN 46032

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Syra Health Corp [ SYRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

3. Date of Earliest Transaction (Month/Day/Year)
01/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Restricted Stock Units	01/05/2026		A		110,537(1)	A	$0.00	110,537	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options	$0.09	01/05/2026		A		257,920		(2)	01/05/2036	Class A Common Stock	257,920	$0	257,920	D

Explanation of Responses:

1. 20% of the RSUs vest one year after date of grant and the remainder vest equally over four years on the anniversary of date of grant beginning one year after date of grant

2. 20% of the options vest one year after date of grant and the remainder vest equally over four years on the anniversary of the date of grant beginning one year after date of grant.

	/s/ Gregory Alexander	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.